Table 3.
Baseline characteristics of included trials for cardiovascular outcomes
| Trial | Year | N | Comparison | Follow-up (months) | Mean age (years) | DM (%) | Stent type | DES (%) |
|---|---|---|---|---|---|---|---|---|
| ABCD46 | 2014 | 630 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 65 | 31 | BES | 100 |
| ACCEL-AMI29 | 2010 | 90 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 62 | 21 | PES>SES>ZES | 100 |
| ACCEL-LOADING-ACS30 | 2012 | 218 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 63 | 23 | DES, BMS | 95 |
| ACCEL-RESISTANCE33 | 2009 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/high-dose clopidogrel | 1 | 63 | 23 | DES | 100 |
| Ahn CM et al47 | 2011 | 130 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 24 | 64 | 22 | SES | 100 |
| Chen YD et al48 | 2006 | 120 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 9 | 58 | 30 | BMS | 0 |
| CIDES49 | 2008 | 280 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 62 | 100 | PES, SES | 100 |
| CILON-T34 | 2011 | 960 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 64 | 34 | PES, ZES | 100 |
| CLEAR50 | 2011 | 120 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 66 | 42 | SES>ZES>PES>EES | 100 |
| CREST51 | 2005 | 705 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 60 | 26 | BMS | 0 |
| DECLARE-DIABETES52 53 | 2008/2010 | 450 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 24 | 61 | 100 | PES, SES | 100 |
| DECLARE-LONG53 54 | 2007/2010 | 450 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 24 | 61 | 33 | PES, SES | 100 |
| DECLARE- LONG II55 | 2011 | 499 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 62 | 35 | ZES | 100 |
| Gao et al35 | 2013 | 428 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 56 | 18 | SES>PES | 100 |
| Guan et al36 | 2012 | 840 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 60 | NR | DES | 100 |
| Han et al56 | 2009 | 1212 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 60 | 22 | BMS, DES | 52 |
| Han et al57 | 2006 | 120 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 3 | 61 | 23 | BMS, DES | 43 |
| HOST-ASSURE37 | 2013 | 3755 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 63 | 32 | ZES-R>EES-PtCr | 100 |
| Hu et al58 | 2013 | 146 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 63 | NR | NR | NR |
| Jin et al39 | 2012 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 62 | 45 | DES | 100 |
| Kim et al59 | 2008 | 109 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 68 | 29 | PES>SES | 100 |
| Kim et al41 | 2007 | 60 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 63 | 29 | SES>PES>others | 100 |
| Kum et al42 | 2009 | 603 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 62 | 26 | DES | 100 |
| Lee et al60 | 2007 | 20 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 56 | 25 | NR | 100 |
| LONG- DES-II61 62 | 2007 | 500 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 9 | 61 | 33 | PES, SES | 100 |
| Lu et al63 | 2006 | 120 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6–9 | 71 | NR | BMS | 0 |
| Lu et al64 | 2007 | 402 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 6 | 61 | 44 | BMS, DES | 85 |
| Min et al10 | 2007 | 59 | Aspirin/clopidogrel or ticlopidine/cilostazol vs aspirin/clopidogrel or ticlopidine | 6 | 62 | 26 | BMS | 0 |
| OPTIMUS-26 | 2008 | 50 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 1 | 64 | 100 | NR | 100 |
| Shen et al65 | 2010 | 160 | Aspirin/Clopidogrel/Cilostazol vs Aspirin/Clopidogrel | 12 | 69 | 100 | DES | 100 |
| Suh et al66 | 2009 | 143 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 25 | 62 | 100 | PES>SES | 100 |
| Wang et al67 | 2005 | 193 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 62 | 28 | BMS | 0 |
| Wang et al68 | 2010 | 164 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 68 | NR | BMS, DES | NR |
| Zang et al69 | 2008 | 263 | Aspirin/clopidogrel/cilostazol vs aspirin/clopidogrel | 12 | 59 | 100 | BMS, DES | 53 |
ABCD, Evaluating Additional Benefit of Cilostazol to Dual Antiplatelet Therapy in Patients with Long or Multivessel Coronary Artery Disease underwent Biolimus-Eluting Stent Implantation; ACS, acute coronary syndrome; AMI, acute myocardial infarction; BES, biolimus-eluting stent; BMS, bare metal stent; CIDES, comparison of cilostazol versus clopidogrel after drug-eluting stenting in diabetic patients; CILON-T, Influence of Cilostazol-based Triple Antiplatelet Therapy on Ischaemic Complication After Drug-eluting Stent Implantation; CLEAR, The Cilostazol Administration Before Percutaneous Coronary Intervention for Reduction of Periprocedural Myonecrosis Trial; CREST, Coronary Stent Restenosis in Patients Treated with Cilostazol; DECLARE-LONG II: Triple Antiplatelet Therapy With Dual Antiplatelet Therapy to Reduce Restenosis After Drug-Eluting Stent Implantation in Long Coronary Lesions; DECLARE-DIABETES, A Randomised Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Diabetic Patients; DECLARE-LONG, Drug-Eluting Stenting Followed by Cilostazol Treatment Reduces Late Restenosis in Patients with Long Coronary Lesions; DES, drug-eluting stent; DM, diabetes mellitus; EES, everolimus-eluting stent; EES-PtCr, everolimus-eluting platinum-chromium alloy stent; LONG-DES, Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent for Patients With Long Coronary Artery Disease; OPTIMUS-2, Impact of Cilostazol on Platelet Function Profiles in Patients with Diabetes Mellitus and Coronary Artery Disease on Dual Antiplatelet Therapy; PES, Paclitaxel-eluting stent; SES, Sirolimus-eluting stent; ZES, Zotarolimus-eluting stent; ZES-R, Zotarolimus-eluting Resolute stent.